Frameshift events predict anti–PD-1/L1 response in head and neck cancerGlenn J. Hanna, Robert I. Haddad, Nicole G. Chau et al.|JCI Insight|2018Cited by 279
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and NeckGlenn J. Hanna, Robert I. Haddad, Anne O’Neill et al.|Clinical Cancer Research|2021Cited by 104
Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neckGlenn J. Hanna, Peter S. Hammerman, Hongye Liu et al.|Oral Oncology|2017Cited by 89